#1BEAUTYHEALTH Q2 2023 Earnings Presentation August 9, 2023 cial TM Hydrafacial Hydr Hydrafacial Hydrafac#2Disclaimer This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward-looking words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "outlook," "forecast" and other similar expressions. These are intended to identify forward-looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company's judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 1, 2023, our Quarterly Report on Form 10-Q filed with the SEC on May 10, 2023 and other filings with the SEC. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise. Non-GAAP Financial Measures In addition to results determined in accordance with accounting principles generally accepted in the United States of America (GAAP), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted selling and marketing expense, adjusted research and development expense, adjusted general and administrative expense, and adjusted EBITDA for purposes of evaluating ongoing operations and for internal planning and forecasting purposes. Management believes that these non-GAAP financial measures, when reviewed collectively with the Company's GAAP financial information, provide useful supplemental information to investors in assessing our operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to non- recurring, unusual items. The Company does not provide a reconciliation of its fiscal 2023 adjusted EBITDA margin guidance to net income (loss), the most directly comparable forward looking GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash stock-based compensation, gains/losses on foreign currency and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2023 adjusted gross margin and adjusted EBITDA margin guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See "Forward-Looking Statements" for additional information. Net sales excluding trade-ups is calculated as net sales excluding the effect of net sales associated with delivery systems sold under a trade-up program. Adjusted cost of sales is calculated as cost of sales excluding the effects of depreciation expense, amortization expense, stock-based compensation expense and other items such as the write-off of discontinued and obsolete product, Syndeo product optimization logistics & service costs and accrual for annual cash incentives. Adjusted gross profit is calculated as gross profit excluding the effects of the adjustments described in adjusted cost of sales above. Adjusted selling and marketing expense is calculated as selling and marketing expense excluding the effects of depreciation expense, amortization expense, stock-based compensation expense and other items such as the accrual for annual cash incentives and severance, restructuring and other. Adjusted research and development expense is calculated as research and development expense excluding the effects of stock-based compensation expense and other items such as the accrual for annual cash incentives and severance, restructuring and other. Adjusted general and administrative expense is calculated as general and administrative expense excluding the effects of depreciation expense, amortization expense, stock-based compensation expense, loss on disposal of assets, transaction related costs, litigation related costs, accrual for annual cash incentives and severance, restructuring and other. k-based compensation expense, interest expense, interest income, other Adjusted EBITDA alculated as net income (loss) excluding effects of (benefit) expense for income taxes, depreciation expense, amortization expense, (income) expense, change in fair value of warrant liability, foreign currency (gain) loss, net, loss on disposal of assets, transaction related costs, write-off of discontinued and obsolete product, litigation related costs, Syndeo product optimization logistics & service costs, accrual for annual cash incentives and severance, restructuring and other. 2 BEAUTYHEALTH™#3Today's agenda 1 2 Opening Remarks | Andrew Stanleick President & Chief Executive Officer Q2 2023 Results | Liyuan Woo Chief Financial Officer H2 2023 Outlook | Andrew Stanleick President & Chief Executive Officer 31 4 5 Q&A Innovation Pipeline | Brad Hauser Chief Operating Officer BEAUTYHEALTH™#4Welcoming new financial leadership 4 Michael Monahan Chief Financial Officer Effective August 10, 2023 15 years as a CFO, 25 years in financial leadership Consumer goods and wellness market Public accounting experience Previous experience Casper Nutrisystem ARTHUR ANDERSEN BEAUTYHEALTH™#5Q2 2023 performance takeaways Re-committing to our core 1 Continued demand for Hydrafacial drives double-digit top- line growth 2 Growing consumer engagement validated by consumables growth and improving key marketing metrics 3 4 5 LO 5 Strength in core international markets, especially China, despite macroeconomic headlines Opex leverage drives adjusted EBITDA performance, but Syndeo teething issues and unfavorable system mix shift create gross margin headwinds Re-affirming 2023 net sales and 2025 long-range financial guidance on strengthened fundamentals; refining 2023 adjusted EBITDA margin to more precise range 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure. $117.5mm +13% YoY Incl. trade-ups Consumables net sales/ YOY growth +34% Net sales +265% Incl. trade-ups $3.4mm GAAP net income Q2 2023 +32% YoY Excl. trade-ups China net sales YOY growth Aided brand $460-480mm/ 18-19% awareness 41% +167% Excl. trade-ups $17.8mm +22% YoY Adjusted EBITDA¹ Q2 2023 $600-700mm / 25-30% FY 2023 FY 2025 Net sales / adjusted EBITDA¹ margin guidance BEAUTYHEALTH™#6Our growth track record Net sales ($mm) $112 6 2018 $167 2019 $119 2020 $260 2021 $366 2022 $460- $480 2023E ~4x Expected net sales growth since 2020 Hydrafacial device install base Number of delivery systems 13,872 10,524 IL 2018 2019 15,689 2020 20,399 2021 25,336 2022 29,670 1H23 ~2x Device footprint growth since 2020 BEAUTYHEALTH™#7Reflecting on key learnings OPPORTUNITIES Syndeo teething issues Inadequate forecasting processes Premature conversion of small distributor markets added unnecessary distraction 7 KEY ACTIONS Syndeo enhancements identified and expected to be completed by early Q4 2023 New financial and operational leadership in place to drive forecasting discipline and improved systems Plan to refine direct market roster; right size distributor relationships BEAUTYHEALTH™#8BeautyHealth is positioned for long-term success. 8 DIFFERENTIATED PRODUCT & TECHNOLOGY Created hydramabrasion category with clinical efficacy and patented technology LOYAL ESTHETICIANS Adored by estheticians for attractive economics, rapid equipment payback, and ability to bundle with other services LEADER IN LARGE, ADDRESSABLE MARKET Omnichannel distribution and favorable global tailwinds provide structural advantages LOVED BY CONSUMERS Accessible price point, immediately gratifying results and dynamic branding drive best- in-class NPS and engagement UNIQUE ECONOMIC MODEL Profitable unit economics on equipment sales and long-tailed, durable recurring cash flow from consumables sales EFFICIENT R&D ENGINE Exciting internal pipeline paired with marquee industry partners attracted to our unique platform and evangelical community BEAUTYHEALTH™#9Q2 2023 Performance Update BEAUTYHEALTH™ Treatment History Details HE Hydrafacial Enthusiast. 04/27/2023 Treatments • Doluxa hydrafacial ACTIV- Treatment Deluxe. Includes: Exfoliation Peel Extractions Booster LightStim Elipse Hydrating Antioxidant BETA-HO DO IT AGAIN Tips: Blue Teal Teal Clear Clear ANTIOX- Personalization 11:34 PM Britenol Glysal Prep RINSEAWAY SCIC ⠀#10Continued demand for Hydrafacial underpins our growth Net sales detail ($mm) Americas APAC EMEA Total Americas APAC EMEA Total Delivery Systems New Trade-Up All Systems $26.3 $28.4 13.3 18.6 14.4 18.5 $54.0 $65.6 10 $2.1; 5.4 4.21 $11.6 Delivery systems volume vs $23.3mm U.S. Syndeo launch in Q2 2022 Number sold New Trade-Up 1,069 610 710 2,389 Delivery Systems Cons. $35.2 Total New Trade-Up All Systems $63.6 +7% (91%) 6.6 25.2 +100% NM 10.1 28.6 +42% NM $51.9 $117.5 +30% (50%) (41%) +180% +84% +1% vs 1,203 launch-driven trade-ups in Q2 2022 % YoY growth New Trade-Up Total 98- 1,167 +25% 179 789 +145% 156 866 433 2,822 (92%) Total (43%) % YoY growth +217% NM NM +100% +64% +56% (64%) +3% 1. Number of delivery systems owned by providers that have purchased consumables in the trailing twelve-month period. Total Cons. incl. Trade-Up excl. Trade-Up +29% (16%) +18% +77% +143% +92% +31% +61% +37% +34% +13% +32% 29,682 Global Hydrafacial install base¹ +29% YoY $22.9K Average Delivery System Selling Price (3%) YoY BEAUTYHEALTH™#11Adjusted EBITDA margin expansion partially offset by temporary gross margin headwinds. Gross margin and adjusted gross margin¹ 11 67.6% 57.8% Q2 2022 Q2 2023 GAAP gross margin I Decrease due to unfavorable mix shift to refurbished systems and duplicative production costs 71.0% 64.8% Q2 2022 Q2 2023 Adjusted gross margin¹ Note: Q2 2022 reflects the impact of immaterial revisions to the financial statements. 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure. Net income (loss) ($mm) $6.3 Q2 2022 Adjusted EBITDA¹ ($mm) $14.6 14.1% Q2 2022 -% margin $3.4 Q2 2023 $17.8 15.1% Q2 2023 BEAUTYHEALTH™#12Generating operating leverage as scale increases Q2 2023 cost detail ($mm) Cost of sales Selling and marketing Research and development General and administrative 12 1. 2. GAAP 02 2023 $49.6 43.0 2.9 35.1 Q2 2022¹ $33.5 44.9 2.6 27.6 Q2 2023 $41.3 36.0 2.0 20.4 Q2 2022¹ $30.1 40.1 1.6 17.1 Adjusted² Reflects the impact of immaterial revisions to the financial statements. Refer to the disclaimer for a discussion of the definition of this measure and appendix for reconciliation to the most appropriate GAAP measure. A Q2 2022 +$11.2 (4.2) +0.5 +3.3 Q2 2023 35.2% 30.6% 1.7% 17.4% % net sales Q2 2022 AQ2 2022 +7.1% improvement in adjusted operating leverage YoY 29.0% 38.8% 1.5% 16.6% +6.1% (8.2%) +0.2% +0.8% BEAUTYHEALTH™#13Q2 2023 balance sheet highlights Cash and cash equivalents Warrants Convertible debt Revolving credit facility Shares outstanding 13 → Approximately $549.7 million cash and cash equivalents on balance sheet (+$17.4 million vs Q1 2023) → Approximately 7 million private warrants outstanding → $750 million 1.25% convertible notes due 2026 → Use of proceeds: capped call transaction, potential future acquisitions, working capital expenditures, and general corporate purposes → Conversion price of $31.76; capped call agreement provides dilution protection up to $47.94 $50 million Senior Secured Credit Facility remains undrawn; current undrawn commitment fee of 25 bps ◆ Allows flexibility for future M&A; ex-US operations unencumbered; convertible debt excluded from covenants Approximately 132.9 million current shares outstanding BEAUTYHEALTH™#14BEAUTYHEALTH™ H2 2023 Outlook Andrew Stanleick President & Chief Executive Officer 8 BEAUTYHEALTH#15Refining our 2023 and re-affirming long-term 2025 outlook $460-480mm FY 2023E net sales Year-to-go net sales bridge ($mm) 15 $86.3 Q1 2023 $117.5 Q2 2023 $110 - $120 24-35% YoY growth Q3 2023E $146 -$156 49 - 59% YoY growth Implied Q4 2023E $460-$480 26 - 31% YoY growth FY 2023E 18 - 19% FY 2023E adjusted EBITDA¹ margin Year-to-go adjusted EBITDA margin bridge (0.6%) Q1 2023 15.1% Q2 2023 Reaffirming long-term 2025 financial guidance 1. Adjusted EBITDA margin is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook. 18% - 20% $20- 24mm Q3 2023E 31% -32% $46- 50mm Implied Q4 2023E 18% - 19% $83 - 91mm FY 2023E BEAUTYHEALTH™#16BEAUTYHEALTH™ Just Getting Started in an Untapped Market Lod NORD#17Unlocking a long-term, high-margin recurring revenue stream with each system placement Consumables net sales by cohort based on year of equipment purchase ($mm) Pre-2017 2017 2018 2019 2020 2021 2022 17 $41 2018 $62 $46 $80 $102 2019 2020 2021 2022 Consumables net sales for the fiscal year ended December 31, 1. Data based on single-system providers in the US. Sample size of 3,249 churned devices. 2. Based on % of active delivery systems sold between 2012-2014. 74% consumables net sales Generated by cohorts older than two years (FY22) Nearly half Systems sold 8-10 years ago still active² Treatment History Details HE Hydrafacial Enthusi hydrafacial ACTIV- BETA-HOT Personalization Child hap BEAUTYHEALTH™#18Penetration of global addressable market is <5% Estimated market penetration Unpenetrated addressable market Penetrated addressable market Implied penetration 18 Growth avenues Points of distribution Source: Management estimates. Americas TAM: ~99K+ ~16% Number of consumers (trial) APAC TAM: ~293K+ ~1% Treatment frequency (loyalty & affinity) Revenue per treatment EMEA TAM: ~52K+ ~7% International presence Global TAM: ~444K+ < 5% Product line extensions BEAUTYHEALTH™#19China: well positioned to capture significant growth 19 Business overview $23.8mm 1H23 revenue Current direct market presence Beijing Shanghail Shenzhen +6 metros Market tailwinds 41% % Chinese consumers expecting to increase spending on health and beauty products (vs global avg 29%)¹ #2 Among all health concerns nationwide is unhealthy skin² 1. PwC 2022 Global Consumer Insights Survey China Report. 2. CBNData. https://www.cbndata.com/report/2800/detail?ls Reading=report&page=1 3. Management estimates. ~2,000 Q2 2023 install base Penetrated market Unpenetrated TAM³ sedan Competitive advantages Gold standard in preventative skin health + consumer activation competency Accessible price deepens recession resiliency Non-medical Registration classification provides flexibility in promotion while having professional endorsement (KOLS, Influencers) BEAUTYHEALTH™#2020 Hydrafacial JUVÉDERM COLLECTION OF FILLERS coolsculpting IN MODE DIAMOND GLOWⓇ® GLOFACIAL BY geneo Generating sustained buzz and momentum 2023YTD Earned Media Value ($mm) $1.5 $0.2 $1.4 $1.1 $0.9 Source: Tribe Dynamics Earned Media Value is a proprietary metric published by Tribe Dynamics used as an influencer marketing metric to quantify the value of social media content. $9.7 BEAUTYHEALTH™#21Generating sustained buzz and momentum Worldwide Google search trends Interest over time 21 100 80 60 40 20 O Jan-22 Source: Google Feb-22 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 M Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 May-23 Jun-23 +10% YTD YOY growth Hydrafacial™ coolsculpting® JUVÉDERM® DIAMOND GLOW GLOFACIAL BY geneo BEAUTYHEALTH™#22Bolstering brand love with dynamic activations Dior powered by Hydrafacial VOGUE TRAVEL Dior's Floating Spa in Paris Offers Facials While Cruising The Seine CHRISTIAN DIOR 22 0 Hydrafac DIOR Hydrafacial DIOR A wellness cruise on the River Seine during Paris Haute Couture Week redefines luxury and relaxation. Syndeo "dresses" in Dior signature white and gold for the occasion. GLOWvolution 2023 Hydracial™ Hydrafacial Source: Tribe Dynamics Earned Media Value is a proprietary metric published by Tribe Dynamics used as an influencer marketing metric to quantify the value of social media content. 9570 Hydrefal GLOWvolution GLOWvolution owTime rafacial A multi-day residency and immersive brand experience for influencers, press, providers, prospects and qualified consumers. Kicked off in New York and Los Angeles with global cities to follow. $3.1mm in Earned Media Value | +1,285% EMV vs. 2022 GLOWvolution tour BEAUTYHEALTH™#23Present wherever consumers seek beauty and health treatments NEWS! CONFOR 23 Hydrafacial Expands to Sephora Australia Now in Sephora Stores on Three Continents SEPHORA T SEPHORA COLLECTION PRAGRANCE VIRTUAL SEPHO ARC ww D 35663 HEIT STY SKINCARE OLDU € IS ydrafacial™ OMNI-CHANNEL PRESENCE Medical Spa Retail Hospitality BEAUTYHEALTH™#24The treatment they ask for by name... 41% Brand awareness¹ rial 60% Conversion More than Botox¹ 24 The Hydratinial Hych Hydrafacial Hydralicial ...and recommend to their friends labelbill Hydrafacial™ TM 98% RealSelf "Worth It"Rating 55 Consumer Net Promoter Score² BEAUTYHEALTH™ Source: Ipsos and RealSelf 1. Base: Consumers of the aesthetic and professional beauty category (n=1001); Brand Aided Awareness. Conversion defined as % of respondents who are aware of and have tried a given brand 2. Consumers of the aesthetic and professional beauty category that have received a Hydrafacial (n=246); "On a scale of 0 to 10, how likely are you to recommend Hydrafacial to a friend or colleague?"#25< Edit Treatment Platinum HydraFacial Exfoliation Instructions Adjust the serum flow valve on your handpiece as needed. Adjust vacuum setting as needed. Use a dab and spread motion prior to the first pass to moisten skin. Use long, fast, 60% overlapping strokes. Make two passes for complete exfoliation, Hold skin taut and apply counter pressure. Device Tip Handpiece Blue Serum Activ-4 ACTIV-4 CLEANSE AHA Exfoliating S Solution exfolia Treatment Pattern Dob-long, Fast, Overlapping Strokes Step 1 Step 4 Step 2 BETA HD CLEAR EXTRACT BHA Defying S Solution de Step 3 ANTIOX + RINSEAWAY HYDRATE Hyaluronic A Antido Mo Solution y Sacide hyalu II Infi 04:54 PM Vacuum 16 START 125450 > Systen C ⠀ DEVICE RIN Hydrafaci Innovation pipeline Brad Hauser Chief Operating Officer BEAUTYHEALTH™#26Creating a future-ready organization. as we mature into a multi-brand ecosystem 26 Brad Hauser Chief Operating Officer Product Marketing Operations Previous experience CUTERAⓇ FACE + BODY AESTHETIC SOLUTIONS soliton SOLTA MEDICAL® ZELTIQ End-to-end product oversight, from innovation to go-to-market BEAUTYHEALTH™#2727 TO Lightstim Elipsa LED mask LightStim / hydrafacial Bew plashe kinaplash Dermatoscope Laser Syndeo is a plug & play platform Oxygen facial BEAUTYHEALTH™#2828 Allegro, connected. The new entry level Hydrafacial Hydrafacial BEAUTYHEALTH™#29Channel and region-specific booster innovations D 0.5 fl oz/15ml e 3-OC Brighten & Firm Eye Cream C+ Collagène Raffermir et Illuminer Crème Contour des Yeux Dr Dennis Gross C+ Collac D 3-0 C Dr Dennis Gross C + Collagen Brighten & Firm Vitamin C Serum C + Collagène Peau Éclatante et Ferme Sérum à la Vitamine C 1.0 fl oz/30ml e Dr Dennis Gross 3-0 C C + Collagen Deep Cream C + Collagen Crème Intense Net Wt 1.7 oz/50g e D Dr Dennis Gross 3-OC C + Collagen Perfect Skin Set & Refresh Mist C+Collagène Brume Rafraîchissante Pour Une Peau Parfaite 3.0 fl oz/88ml e#30Image for illustrative purposes only. Not actual final saleable product. Hydrafacial Hydrafacial Skincare at home Hydrafacial BEAUTYHEALTH™#31OHSA 101 Entering hair salons with a custom Keravive device Keravive Scalp HydraFacial Cleanse & Exfoliate Instructions Idently main areas of concern. Once you have identified the areabl if necessory, cip or hold the sounding hair sections so as not to interfere with the working area. Start of the hairline or own performing short strokes and making contact with the scalp. Choose the direction that gives you the best contact with the scolp. Work in small sections to exfoliate as much of the scalp as possible, un the scalp tuns a healthy pirk color Device Handpiece Tip Blue Hydrafacial Serum Bella HD A BEAUTYHEALTH™#32Image for illustrative purposes only. Not actual final app. Hydrafacial Hey Amber! Earn as you glow → Skin Survey Take a Skin Survey Get skin treatment options and advice based off of your results! What's New Home Earn Rewards Treatment Recommendations Learn € Prep Book R Connecting our ecosystem through loyalty Hydrafacial 10pts 5 points left You're 5 points away from a Reward Earn Rewards BEAUTYHEALTH™#33Closing remarks Please join us BEAUTYHEALTH™ Investor Day H1 2024 Date to be announced BEAUTYHEALTH™#3434 Plate Valeria Fernandez - Hydrafaci hydrafacial GLYSAL PREP SOBIN Q&A Hydrafacial THE BEST SKIN OF YOUR LIFE STARTS HERE 04:52 PM BEAUTYHEALTH™#35Q2 2023 performance takeaways Re-committing to our core 1 Continued demand for Hydrafacial drives double-digit top- line growth 2 Growing consumer engagement validated by consumables growth and improving key marketing metrics 3 4 5 35 Strength in core international markets, especially China, despite macroeconomic headlines Opex leverage drives adjusted EBITDA performance, but Syndeo teething issues and unfavorable system mix shift create gross margin headwinds Re-affirming 2023 net sales and 2025 long-range financial guidance on strengthened fundamentals; refining 2023 adjusted EBITDA margin to more precise range 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure. $117.5mm +13% YoY Incl. trade-ups Consumables net sales/ YOY growth +34% Net sales +265% Incl. trade-ups $3.4mm GAAP net income Q2 2023 +32% YoY Excl. trade-ups China net sales YOY growth Aided brand $460-480mm/ 18-19% awareness 41% +167% Excl. trade-ups $17.8mm +22% YoY Adjusted EBITDA¹ Q2 2023 $600-700mm / 25-30% FY 2023 FY 2025 Net sales / adjusted EBITDA¹ margin guidance BEAUTYHEALTH™#3636 Appendix BEAUTYHEALTH™#37Reconciliation of GAAP to non-GAAP measures Reconciliation of cost of sales to adjusted cost of sales and gross profit to adjusted gross profit Unaudited ($ in millions) Net sales Cost of sales Adjusted to exclude the following: Depreciation expense Amortization expense Stock-based compensation expense Write-off of discontinued and obsolete product Syndeo product optimization logistics & service costs Accrual for annual cash incentives² Total adjustments to cost of sales Adjusted cost of sales Gross profit Gross profit margin Total adjustments to cost of sales Adjusted gross profit Adjusted gross profit margin 37 Note: Amounts may not sum due to rounding. Reflects the impact of immaterial revisions to the financial statements. Amount in the prior period adjusted for comparability purposes. 1. 2. Three months ended June 30, 2023 $117.5 49.6 0.6 4.5 0.4 1.0 1.4 0.4 8.3 $41.3 $67.9 57.8% 8.3 $76.2 64.8% 2022¹ $103.5 33.5 0.6 2.4 0.2 0.3 3.4 $30.1 $70.0 67.6% 3.4 $73.5 71.0% Six months ended June 30, 2023 $203.8 81.8 1.1 6.9 0.7 4.0 1.4 0.4 14.6 $67.2 $122.0 59.9% 14.6 $136.5 67.0% 2022¹ $179.0 58.0 1.0 4.6 0.4 T 0.6 6.7 $51.4 $120.9 67.6% 6.7 $127.6 71.3% BEAUTYHEALTH™#38Reconciliation of GAAP to non-GAAP measures (cont'd) Reconciliation of selling and marketing expense to adjusted selling and marketing expense Unaudited ($ in millions) Net sales Selling and marketing expense % net sales Adjusted to exclude the following: Depreciation expense Amortization expense Stock-based compensation expense Accrual for annual cash incentives ² Severance, restructuring and other Adjusted selling and marketing expense % net sales 38 Note: Amounts may not sum due to rounding. Reflects the impact of immaterial revisions to the financial statements. Amount in the prior period adjusted for comparability purposes. 1. 2. Three months ended June 30, 2023 $117.5 $43.0 36.6% 1.1 1.0 1.7 1.8 1.5 $36.0 30.6% 2022¹ $103.5 $44.9 43.3% 0.2 0.6 2.0 1.1 0.8 $40.1 38.8% Six months ended June 30, 2023 $203.8 $81.7 40.1% 1.4 1.6 3.5 1.8 1.7 $71.8 35.2% 2022¹ $179.0 $81.3 45.4% 0.7 1.3 4.8 1.4 0.8 $72.2 40.4% BEAUTYHEALTH™#39Reconciliation of GAAP to non-GAAP measures (cont'd) Reconciliation of research and development expense to adjusted research and development expense Unaudited ($ in millions) Net sales Research and development expense % net sales Adjusted to exclude the following: Stock-based compensation expense Accrual for annual cash incentives Severance, restructuring and other Adjusted research and development expense % net sales 39 2 Note: Amounts may not sum due to rounding. Reflects the impact of immaterial revisions to the financial statements. Amount in the prior period adjusted for comparability purposes. 1. 2. Three months ended June 30, 2023 $117.5 $2.9 2.5% 0.4 0.4 0.1 $2.0 1.7% 2022¹ $103.5 $2.6 2.5% 0.3 0.8 $1.6 1.5% Six months ended June 30, 2023 $203.8 $5.2 2.6% 0.4 0.4 0.5 $4.0 1.9% 2022¹ $179.0 $4.8 2.7% 0.4 0.6 $3.8 2.1% BEAUTYHEALTH™#40Reconciliation of GAAP to non-GAAP measures (cont'd) Reconciliation of general and administrative expense to adjusted general and administrative expense Unaudited ($ in millions) Net sales General and administrative expense % net sales Adjusted to exclude the following: Depreciation expense Amortization expense Stock-based compensation expense Loss on disposal of assets Transaction related costs Litigation related costs Accrual for annual cash incentives2 Severance, restructuring and other Adjusted general and administrative expense % net sales 40 Note: Amounts may not sum due to rounding. Reflects the impact of immaterial revisions to the financial statements. Amount in the prior period adjusted for comparability purposes. 1. 2. Three months ended June 30, 2023 $117.5 $35.1 29.9% 0.9 2.3 6.1 0.8 0.5 2.8 1.3 $20.4 17.4% 2022¹ $103.5 $27.6 26.6% 1.1 0.9 3.9 1.0 2.0 1.5 0.1 $17.1 16.6% Six months ended June 30, 2023 $203.8 65.5 32.1% 1.9 3.7 7.6 0.1 0.8 1.5 2.8 3.5 $43.6 21.4% 2022¹ $179.0 53.8 30.1% 1.5 1.8 7.8 1.0 3.0 3.4 2.1 $33.3 18.6% BEAUTYHEALTH™#41Reconciliation of GAAP to non-GAAP measures (cont'd) Reconciliation of net income to adjusted EBITDA Three months ended June 30, 2023 $117.5 Unaudited ($in millions) Net sales Net income (loss) Net income (loss) margin Adjusted to exclude the following: (Benefit) expense for income taxes Depreciation expense Amortization expense Stock-based compensation expense Interest expense Interest income Other (income) expense, net Change in fair value of warrant liability Foreign currency (gain) loss, net Loss on disposal of assets Transaction related costs Write-off of discontinued and obsolete product Litigation related costs Syndeo product optimization logistics & service costs Accrual for annual cash incentives² Severance, restructuring and other Adjusted EBITDA Adjusted EBITDA margin 41 Note: Amounts may not sum due to rounding. Reflects the impact of immaterial revisions to the financial statements. Amount in the prior period adjusted for comparability purposes. 1. 2. $3.4 2.9% (2.2) 2.6 7.8 8.5 3.4 (5.7) (0.0) (11.6) (0.4) 0.8 1.0 0.5 1.4 5.4 2.8 $17.8 15.1% 2022¹ $103.5 $6.3 6.1% 0.1 1.9 3.9 6.4 3.2 (0.7) (0.9) (15.2) 2.2 1.0 2.0 3.6 0.9 $14.6 14.1% Six months ended June 30, 2023 $203.8 ($16.9) (8.3%) (5.9) 4.5 12.2 12.1 6.8 (10.0) (0.5) (2.5) (1.5) 0.1 0.8 4.0 1.5 1.4 5.4 5.7 $17.3 8.5% 2022¹ $179.0 $37.8 21.1% 2.7 3.3 7.7 13.4 6.6 (0.7) 0.0 (67.2) 1.8 1.0 3.0 6.1 2.9 $18.3 10.2% BEAUTYHEALTH™#42BEAUTYHEALTH TM